BACKGROUND: Patients with prostate cancer with a pre-operative prostate-specific antigen (PSA) >15 ng/ml who undergo radical retropubic prostatectomy (RRP) generally do not have a good outcome, yet may have organ-confined cancer and should be offered the option of surgery. AIM: To assess the outcome of patients who underwent RRP with a pre-operative PSA >15 ng/ml. METHODS: Thirty-four patients, mean pre-operative PSA: 25.46 ng/ml (15.03-76.6) and mean Gleason score: 6.4 (5-9) were assessed. RESULTS: Two groups were identified. Group I: 41% (14/34) have no biochemical recurrence to mean follow up of 58 months (30-106). Mean PSA: 18.8 ng/ml (15.03-25.84). Mean Gleason score: 6.1 (5-7). Clinical stage: T1c in 80%. No patient had seminal vesicle or lymph node involvement. Group II: 59% (20/34) have biochemical recurrence or died (3) from their disease to mean follow up of 66 months (36-98). Mean PSA: 28.9 ng/ml (15.28-76.6). Mean Gleason score: 6.7 (5-9). Clinical stage: T1c in 25%. Eleven patients had seminal vesicle (8) involvement or positive lymph nodes (3) or both (2). CONCLUSION: RRP seems feasible in patients whose pre-operative PSA is between 15 and 25 ng/ml with stage T1c, Gleason score < or = 7 and negative lymph node frozen section.
BACKGROUND:Patients with prostate cancer with a pre-operative prostate-specific antigen (PSA) >15 ng/ml who undergo radical retropubic prostatectomy (RRP) generally do not have a good outcome, yet may have organ-confined cancer and should be offered the option of surgery. AIM: To assess the outcome of patients who underwent RRP with a pre-operative PSA >15 ng/ml. METHODS: Thirty-four patients, mean pre-operative PSA: 25.46 ng/ml (15.03-76.6) and mean Gleason score: 6.4 (5-9) were assessed. RESULTS: Two groups were identified. Group I: 41% (14/34) have no biochemical recurrence to mean follow up of 58 months (30-106). Mean PSA: 18.8 ng/ml (15.03-25.84). Mean Gleason score: 6.1 (5-7). Clinical stage: T1c in 80%. No patient had seminal vesicle or lymph node involvement. Group II: 59% (20/34) have biochemical recurrence or died (3) from their disease to mean follow up of 66 months (36-98). Mean PSA: 28.9 ng/ml (15.28-76.6). Mean Gleason score: 6.7 (5-9). Clinical stage: T1c in 25%. Eleven patients had seminal vesicle (8) involvement or positive lymph nodes (3) or both (2). CONCLUSION: RRP seems feasible in patients whose pre-operative PSA is between 15 and 25 ng/ml with stage T1c, Gleason score < or = 7 and negative lymph node frozen section.
Authors: A V D'Amico; R Whittington; S B Malkowicz; M Weinstein; J E Tomaszewski; D Schultz; M Rhude; S Rocha; A Wein; J P Richie Journal: J Urol Date: 2001-12 Impact factor: 7.450
Authors: R A Badalament; M C Miller; P A Peller; D C Young; D K Bahn; P Kochie; G J O'Dowd; R W Veltri Journal: J Urol Date: 1996-10 Impact factor: 7.450
Authors: Anthony V D'Amico; Richard Whittington; S Bruce Malkowicz; Kerri Cote; Marian Loffredo; Delray Schultz; Ming-Hui Chen; John E Tomaszewski; Andrew A Renshaw; Alan Wein; Jerome P Richie Journal: Cancer Date: 2002-07-15 Impact factor: 6.860
Authors: Kien Nguyen; Stephanie Eltz; Sarah J Drouin; Eva Comperat; François Audenet; Raphaele Renard-Penna; Marc-Olivier Bitker; Emmanuel Chartier-Kastler; François Richard; Olivier Cussenot; Morgan Rouprêt Journal: World J Urol Date: 2009-05-23 Impact factor: 4.226